Glycyrrhizin, inhibitor of high mobility group box-1, attenuates monocrotaline-induced pulmonary hypertension and vascular remodeling in rats

Respiratory Research

Volumn 15, Issue 1, 2014, Pages

  Yang, Pil Sung ^a   Kim, Dae Hoon ^a   Lee, Yong Joon ^b   Lee, Sang Eun ^a   Kang, Won Jun ^b   Chang, Hyuk Jae ^a,c   Shin, Jeon Soo ^b,c  

^a Yonsei University College of Medicine   (South Korea)

^b Yonsei University College of Medicine   (South Korea)

^c Yonsei University College of Medicine   (South Korea)

Author keywords

Glycyrrhizin; High mobility group box 1 (HMGB1); Inflammation; Pulmonary hypertension; Pulmonary vascular remodeling

Indexed keywords

GLYCYRRHIZIC ACID; HIGH MOBILITY GROUP B1 PROTEIN; MONOCROTALINE; SODIUM CHLORIDE; ANTIHYPERTENSIVE AGENT; ENDOTHELIN 1; HBP1 PROTEIN, RAT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DRUG TARGETING; HEART RIGHT VENTRICLE HYPERTROPHY; HEART RIGHT VENTRICLE PRESSURE; IMMUNOHISTOCHEMISTRY; INFLAMMATION; LUNG BLOOD VESSEL; LUNG PARENCHYMA; MALE; NONHUMAN; PROTEIN EXPRESSION; PULMONARY ARTERY; PULMONARY HYPERTENSION; RAT; SPRAGUE DAWLEY RAT; SURVIVAL TIME; SYSTOLIC BLOOD PRESSURE; VASCULAR REMODELING; ANIMAL; ANTAGONISTS AND INHIBITORS; ARTERIAL PRESSURE; CELL CULTURE; CELL PROLIFERATION; CHEMICALLY INDUCED; DISEASE MODEL; DOSE RESPONSE; DRUG EFFECTS; HEART RIGHT VENTRICLE FUNCTION; HUMAN; HYPERTENSION, PULMONARY; HYPERTROPHY, RIGHT VENTRICULAR; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PNEUMONIA; PREVENTION AND CONTROL; TIME FACTOR; VASCULAR SMOOTH MUSCLE;

ANIMALS; ANTIHYPERTENSIVE AGENTS; ARTERIAL PRESSURE; CELL PROLIFERATION; CELLS, CULTURED; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIN-1; GLYCYRRHIZIC ACID; HMGB1 PROTEIN; HUMANS; HYPERTENSION, PULMONARY; HYPERTROPHY, RIGHT VENTRICULAR; MALE; MONOCROTALINE; MUSCLE, SMOOTH, VASCULAR; PNEUMONIA; PULMONARY ARTERY; RATS, SPRAGUE-DAWLEY; TIME FACTORS; VASCULAR REMODELING; VENTRICULAR DYSFUNCTION, RIGHT; VENTRICULAR FUNCTION, RIGHT;

EID: 84978036843     PISSN: 14659921     EISSN: 1465993X     Source Type: Journal    
DOI: 10.1186/s12931-014-0148-4     Document Type: Article

References (39)

1. Rubin LJ: Primary pulmonary hypertension. N Engl J Med. 1997, 336: 111-117. 10.1056/NEJM199701093360207.
2. Benedict N, Seybert A, Mathier MA: Evidence-based pharmacologic management of pulmonary arterial hypertension. Clin Ther. 2007, 29: 2134-2153. 10.1016/j.clinthera.2007.10.009.
3. Ryerson CJ, Nayar S, Swiston JR, Sin DD: Pharmacotherapy in pulmonary arterial hypertension: a systematic review and meta-analysis. Respir Res. 2010, 11: 12-10.1186/1465-9921-11-12.
4. Hassoun PM, Mouthon L, Barbera JA, Eddahibi S, Flores SC, Grimminger F, Jones PL, Maitland ML, Michelakis ED, Morrell NW, Newman JH, Rabinovitch M, Schermuly R, Stenmark KR, Voelkel NF, Yuan JX, Humbert M: Inflammation, growth factors, and pulmonary vascular remodeling. J Am Coll Cardiol. 2009, 54: S10-S19. 10.1016/j.jacc.2009.04.006.
5. Price LC, Wort SJ, Perros F, Dorfmuller P, Huertas A, Montani D, Cohen-Kaminsky S, Humbert M: Inflammation in pulmonary arterial hypertension. Chest. 2012, 141: 210-221. 10.1378/chest.11-0793.
6. Tuder RM, Archer SL, Dorfmuller P, Erzurum SC, Guignabert C, Michelakis E, Rabinovitch M, Schermuly R, Stenmark KR, Morrell NW: Relevant issues in the pathology and pathobiology of pulmonary hypertension. J Am Coll Cardiol. 2013, 62: D4-D12. 10.1016/j.jacc.2013.10.025.
7. Groth A, Vrugt B, Brock M, Speich R, Ulrich S, Huber LC: Inflammatory cytokines in pulmonary hypertension. Respir Res. 2014, 15: 47-10.1186/1465-9921-15-47.
8. Hassoun PM: Inflammation in pulmonary arterial hypertension: is it time to quell the fire?. Eur Respir J. 2014, 43: 685-688. 10.1183/09031936.00006014.
9. Li J, Kokkola R, Tabibzadeh S, Yang R, Ochani M, Qiang X, Harris HE, Czura CJ, Wang H, Ulloa L, Wang H, Warren HS, Moldawer LL, Fink MP, Andersson U, Tracey KJ, Yang H: Structural basis for the proinflammatory cytokine activity of high mobility group box 1. Mol Med. 2003, 9: 37-45.
10. Ulloa L, Messmer D: High-mobility group box 1 (HMGB1) protein: friend and foe. Cytokine Growth Factor Rev. 2006, 17: 189-201. 10.1016/j.cytogfr.2006.01.003.
11. Scaffidi P, Misteli T, Bianchi ME: Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature. 2002, 418: 191-195. 10.1038/nature00858.
12. Yang H, Ochani M, Li J, Qiang X, Tanovic M, Harris HE, Susarla SM, Ulloa L, Wang H, DiRaimo R, Czura CJ, Roth J, Warren HS, Fink MP, Fenton MJ, Andersson U, Tracey KJ: Reversing established sepsis with antagonists of endogenous high-mobility group box 1. Proc Natl Acad Sci U S A. 2004, 101: 296-301. 10.1073/pnas.2434651100.
13. Wang H, Bloom O, Zhang M, Vishnubhakat JM, Ombrellino M, Che J, Frazier A, Yang H, Ivanova S, Borovikova L, Manogue KR, Faist E, Abraham E, Andersson J, Andersson U, Molina PE, Abumrad NN, Sama A, Tracey KJ: HMG-1 as a late mediator of endotoxin lethality in mice. Science. 1999, 285: 248-251. 10.1126/science.285.5425.248.
14. van Zoelen MA, Yang H, Florquin S, Meijers JC, Akira S, Arnold B, Nawroth PP, Bierhaus A, Tracey KJ, van der Poll T: Role of toll-like receptors 2 and 4, and the receptor for advanced glycation end products in high-mobility group box 1-induced inflammation in vivo. Shock. 2009, 31: 280-284. 10.1097/SHK.0b013e318186262d.
15. van Beijnum JR, Buurman WA, Griffioen AW: Convergence and amplification of toll-like receptor (TLR) and receptor for advanced glycation end products (RAGE) signaling pathways via high mobility group B1 (HMGB1). Angiogenesis. 2008, 11: 91-99. 10.1007/s10456-008-9093-5.
16. Porto A, Palumbo R, Pieroni M, Aprigliano G, Chiesa R, Sanvito F, Maseri A, Bianchi ME: Smooth muscle cells in human atherosclerotic plaques secrete and proliferate in response to high mobility group box 1 protein. FASEB J. 2006, 20: 2565-2566. 10.1096/fj.06-5867fje.
17. Inoue K, Kawahara K, Biswas KK, Ando K, Mitsudo K, Nobuyoshi M, Maruyama I: HMGB1 expression by activated vascular smooth muscle cells in advanced human atherosclerosis plaques. Cardiovasc Pathol. 2007, 16: 136-143. 10.1016/j.carpath.2006.11.006.
18. Treutiger CJ, Mullins GE, Johansson AS, Rouhiainen A, Rauvala HM, Erlandsson-Harris H, Andersson U, Yang H, Tracey KJ, Andersson J, Palmblad JE: High mobility group 1 B-box mediates activation of human endothelium. J Intern Med. 2003, 254: 375-385. 10.1046/j.1365-2796.2003.01204.x.
19. Fiuza C, Bustin M, Talwar S, Tropea M, Gerstenberger E, Shelhamer JH, Suffredini AF: Inflammation-promoting activity of HMGB1 on human microvascular endothelial cells. Blood. 2003, 101: 2652-2660. 10.1182/blood-2002-05-1300.
20. Bauer EM, Shapiro R, Zheng H, Ahmad F, Ishizawar D, Comhair SA, Erzurum SC, Billiar TR, Bauer PM: High mobility group box 1 contributes to the pathogenesis of experimental pulmonary hypertension via activation of Toll-like receptor 4. Mol Med. 2012, 18: 1509-1518. 10.2119/molmed.2012.00283.
21. Krahenbuhl S, Hasler F, Krapf R: Analysis and pharmacokinetics of glycyrrhizic acid and glycyrrhetinic acid in humans and experimental animals. Steroids. 1994, 59: 121-126. 10.1016/0039-128X(94)90088-4.
22. Kimura M, Moro T, Motegi H, Maruyama H, Sekine M, Okamoto H, Inoue H, Sato T, Ogihara M: In vivo glycyrrhizin accelerates liver regeneration and rapidly lowers serum transaminase activities in 70% partially hepatectomized rats. Eur J Pharmacol. 2008, 579: 357-364. 10.1016/j.ejphar.2007.10.073.
23. Schermuly RT, Yilmaz H, Ghofrani HA, Woyda K, Pullamsetti S, Schulz A, Gessler T, Dumitrascu R, Weissmann N, Grimminger F, Seeger W: Inhaled iloprost reverses vascular remodeling in chronic experimental pulmonary hypertension. Am J Respir Crit Care Med. 2005, 172: 358-363. 10.1164/rccm.200502-296OC.
24. Palumbo R, Sampaolesi M, De Marchis F, Tonlorenzi R, Colombetti S, Mondino A, Cossu G, Bianchi ME: Extracellular HMGB1, a signal of tissue damage, induces mesoangioblast migration and proliferation. J Cell Biol. 2004, 164: 441-449. 10.1083/jcb.200304135.
25. Wang H, Yang H, Tracey KJ: Extracellular role of HMGB1 in inflammation and sepsis. J Intern Med. 2004, 255: 320-331. 10.1111/j.1365-2796.2003.01302.x.
26. Meyrick B, Reid L: Development of pulmonary arterial changes in rats fed Crotalaria spectabilis. Am J Pathol. 1979, 94: 37-50.
27. Stenmark KR, Meyrick B, Galie N, Mooi WJ, McMurtry IF: Animal models of pulmonary arterial hypertension: the hope for etiological discovery and pharmacological cure. Am J Physiol Lung Cell Mol Physiol. 2009, 297: L1013-L1032. 10.1152/ajplung.00217.2009.
28. Luan ZG, Zhang H, Yang PT, Ma XC, Zhang C, Guo RX: HMGB1 activates nuclear factor-kappaB signaling by RAGE and increases the production of TNF-alpha in human umbilical vein endothelial cells. Immunobiology. 2010, 215: 956-962. 10.1016/j.imbio.2009.11.001.
29. Quehenberger P, Bierhaus A, Fasching P, Muellner C, Klevesath M, Hong M, Stier G, Sattler M, Schleicher E, Speiser W, Nawroth PP: Endothelin 1 transcription is controlled by nuclear factor-kappaB in AGE-stimulated cultured endothelial cells. Diabetes. 2000, 49: 1561-1570. 10.2337/diabetes.49.9.1561.
30. Deane R, Du Yan S, Submamaryan RK, LaRue B, Jovanovic S, Hogg E, Welch D, Manness L, Lin C, Yu J, Zhu H, Ghiso J, Frangione B, Stern A, Schmidt AM, Armstrong DL, Arnold B, Liliensiek B, Nawroth P, Hofman F, Kindy M, Stern D, Zlokovic B: RAGE mediates amyloid-beta peptide transport across the blood-brain barrier and accumulation in brain. Nat Med. 2003, 9: 907-913. 10.1038/nm890.
31. Yamamoto Y, Harashima A, Saito H, Tsuneyama K, Munesue S, Motoyoshi S, Han D, Watanabe T, Asano M, Takasawa S, Okamoto H, Shimura S, Karasawa T, Yonekura H, Yamamoto H: Septic shock is associated with receptor for advanced glycation end products ligation of LPS. J Immunol. 2011, 186: 3248-3257. 10.4049/jimmunol.1002253.
32. Lee SH, Channick RN: Endothelin antagonism in pulmonary arterial hypertension. Semin Respir Crit Care Med. 2005, 26: 402-408. 10.1055/s-2005-916155.
33. Degryse B, Bonaldi T, Scaffidi P, Muller S, Resnati M, Sanvito F, Arrigoni G, Bianchi ME: The high mobility group (HMG) boxes of the nuclear protein HMG1 induce chemotaxis and cytoskeleton reorganization in rat smooth muscle cells. J Cell Biol. 2001, 152: 1197-1206. 10.1083/jcb.152.6.1197.
34. Sitia G, Iannacone M, Muller S, Bianchi ME, Guidotti LG: Treatment with HMGB1 inhibitors diminishes CTL-induced liver disease in HBV transgenic mice. J Leukoc Biol. 2007, 81: 100-107. 10.1189/jlb.0306173.
35. Mollica L, De Marchis F, Spitaleri A, Dallacosta C, Pennacchini D, Zamai M, Agresti A, Trisciuoglio L, Musco G, Bianchi ME: Glycyrrhizin binds to high-mobility group box 1 protein and inhibits its cytokine activities. Chem Biol. 2007, 14: 431-441. 10.1016/j.chembiol.2007.03.007.
36. van Rossum TG, Vulto AG, de Man RA, Brouwer JT, Schalm SW: Review article: glycyrrhizin as a potential treatment for chronic hepatitis C. Aliment Pharmacol Ther. 1998, 12: 199-205. 10.1046/j.1365-2036.1998.00309.x.
37. Manns MP, Wedemeyer H, Singer A, Khomutjanskaja N, Dienes HP, Roskams T, Goldin R, Hehnke U, Inoue H, European SSG: Glycyrrhizin in patients who failed previous interferon alpha-based therapies: biochemical and histological effects after 52 weeks. J Viral Hepat. 2012, 19: 537-546. 10.1111/j.1365-2893.2011.01579.x.
38. Ruszymah BH, Nabishah BM, Aminuddin S, Khalid BA: Effects of glycyrrhizic acid on right atrial pressure and pulmonary vasculature in rats. Clin Exp Hypertens. 1995, 17: 575-591. 10.3109/10641969509037425.
39. Aharinejad S, Schraufnagel DE, Bock P, MacKay CA, Larson EK, Miksovsky A, Marks SC: Spontaneously hypertensive rats develop pulmonary hypertension and hypertrophy of pulmonary venous sphincters. Am J Pathol. 1996, 148: 281-290.